Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.

Abstract

OBJECTIVE:

The aim of this study was to evaluate the activity of bevacizumab in a cohort of women with recurrent low-grade serous carcinoma of the ovary or peritoneum.

METHODS:

This single-institution retrospective study assessed all patients at MD Anderson Cancer Center with recurrent low-grade serous ovarian or peritoneal cancer who received bevacizumab from 2007 to 2016. Study endpoints included best response, median progression-free survival, median overall survival, and toxicity.

RESULTS:

Forty patients received 45 separate "patient-regimens." Most received bevacizumab in combination with chemotherapy. Complete response (CR) was seen in 7.5%, while 40% had partial responses (PR) and 30% achieved stable disease (SD). Disease progression occurred in nine patients (22.5%). Overall response rate (CR+PR) to bevacizumab-containing regimens was 47.5%. Clinical benefit (CR+PR+SD) was seen in 77.5% of patients. Median progression free survival was 10.2months (95% CI 7.9, 12.4). Median overall survival was 34.6months (95% CI 29.5, 39.7). Fifteen patients discontinued bevacizumab related to toxicity.

CONCLUSIONS:

Bevacizumab, most often in combination with chemotherapy, has activity in recurrent low-grade ovarian cancer and should be considered a treatment option for these patients. Further investigation into the most effective chemotherapeutic agent in combination with bevacizumab is warranted.

• Authors: Heather J Dalton, Nicole D Fleming, Charlotte C Sun, Priya Bhosale, Kathleen M Schmeler, David M Gershenson
• Journal: Gynecologic oncology (Gynecol Oncol) Vol. 145 Issue 1 Pg. 37-40 (04 2017) ISSN: 1095-6859 [Electronic] United States
• PMID: 28139261 (Publication Type: Journal Article)
• Copyright: Copyright © 2017 Elsevier Inc. All rights reserved.

Chemical References

• Aromatase Inhibitors
• Phenylurea Compounds
• Deoxycytidine
• Niacinamide
• Bevacizumab
• Cyclophosphamide
• Sorafenib
• Carboplatin
• Paclitaxel
• Gemcitabine

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Aromatase Inhibitors (administration & dosage)
• Bevacizumab (administration & dosage)
• Carboplatin (administration & dosage)
• Cyclophosphamide (administration & dosage)
• Databases, Factual
• Deoxycytidine (administration & dosage, analogs & derivatives)
• Disease-Free Survival
• Female
• Humans
• Middle Aged
• Neoplasm Recurrence, Local (drug therapy)
• Neoplasms, Cystic, Mucinous, and Serous (drug therapy)
• Niacinamide (administration & dosage, analogs & derivatives)
• Ovarian Neoplasms (drug therapy)
• Paclitaxel (administration & dosage)
• Peritoneal Neoplasms (drug therapy)
• Phenylurea Compounds (administration & dosage)
• Retrospective Studies
• Sorafenib
• Young Adult
• Gemcitabine